No Data
Reviva Pharm Holdings Price Target Maintained With a $14.00/Share by HC Wainwright & Co.
Reviva Pharm Holdings Price Target Maintained With a $14.00/Share by HC Wainwright & Co.
Express News | Reviva Granted A European Patent Covering The Use Of Brilaroxazine In Treatment Of Pulmonary Hypertension
Express News | Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension
HC Wainwright & Co. Reiterates Buy on Reviva Pharmaceuticals, Maintains $14 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains $14 price target.
H.C. Wainwright Maintains Reviva Pharmaceuticals(RVPH.US) With Buy Rating, Cuts Target Price to $14
H.C. Wainwright analyst Ram Selvaraju maintains $Reviva Pharmaceuticals(RVPH.US)$ with a buy rating, and adjusts the target price from $20 to $14.According to TipRanks data, the analyst has a success
Reviva Pharm Holdings Is Maintained at Buy by HC Wainwright & Co.
Reviva Pharm Holdings Is Maintained at Buy by HC Wainwright & Co.